Once the Allen facility begins operations as an outsourcing facility, physicians, hospitals and ambulatory surgical centers will have the opportunity to prescribe and receive certain of Imprimis' proprietary compounded formulations with greater ease and without the time delays associated with the current requirement of providing patient-specific prescriptions and related shipping times. Imprimis' Texas facility is expected to be completed and dispensing certain prescriptions as an outsourcing facility on or before February 1, 2016. In the meantime, the pharmacy will continue its current operations without disruption of service during construction.
"We believe this is the future for sterile compounding pharmacies and we have been advocates of the new law and increased FDA oversight to ensure public confidence in quality and patient safety,” said Mark Baum, chief executive officer, Imprimis. “Fortunately, our Allen, TX facility was a very good candidate for a low cost upgrade to a 503B outsourcing facility given the quality of the existing compounding infrastructure we recently purchased.”
In addition, the company says it intends to open and qualify its larger, state-of-the-art Roxbury, NJ outsourcing facility during the first quarter of 2016.
